Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Type 1 or type 2 diabetes~* Diabetic macular edema~Exclusion criteria:~* Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)~* Recent laser photocoagulation in the study eye~* Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye~Other protocol-defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren 300 mg (Type: EXPERIMENTAL): Aliskiren 300 mg once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).